In September, the American Psychiatric Association (APA) released a list of common, but potentially dangerous and inappropriate, uses for antipsychotics.
The FDA has approved vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD). Brintellix is a novel antidepressant thought to work by enhancing serotonergic acitivty as a serotonin (5-HT) reuptake inhibitor and agonist of the 5-HT1A receptor, among other mechanisms.
Scientists have discovered that the brains of mice clean toxins from between cells while they are sleeping. During sleep, the space between brain cells increases by about 60%, allowing the glymphatic system, or the brain’s “plumbing” system, to flush the brain with fluid.
In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.
More than 75% of cases of child abuse in the US involve neglect, according to a consensus report from the Institute of Medicine released in September 2013.
Ten percent of high school seniors report drinking more than 10 drinks at one time, and 5.6% report drinking more than 15, according to a recent study in JAMA Pediatrics (Patrick ME et al, Online First September 16, 2013).
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
